Exploring 3 US High Growth Tech Stocks For Potential Portfolio Enhancement
As the U.S. stock market experiences mixed movements, with the S&P 500 and Nasdaq on winning streaks amid easing global trade tensions and stable economic data, investors are closely monitoring high-growth tech stocks for potential opportunities. In this dynamic environment, identifying promising tech companies that can enhance a portfolio involves considering factors such as innovation potential, scalability, and resilience to broader market fluctuations.
Name
Revenue Growth
Earnings Growth
Growth Rating
Super Micro Computer
26.28%
37.43%
★★★★★★
Ardelyx
20.57%
59.97%
★★★★★★
Legend Biotech
26.73%
59.51%
★★★★★★
Travere Therapeutics
25.39%
64.80%
★★★★★★
TG Therapeutics
25.99%
38.42%
★★★★★★
Alnylam Pharmaceuticals
23.67%
61.11%
★★★★★★
AVITA Medical
27.28%
60.66%
★★★★★★
Alkami Technology
20.54%
76.67%
★★★★★★
Ascendis Pharma
35.16%
60.26%
★★★★★★
Lumentum Holdings
21.59%
110.32%
★★★★★★
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Autodesk, Inc. offers 3D design, engineering, and entertainment technology solutions globally with a market cap of approximately $63.54 billion.
Operations: The company generates revenue primarily from its CAD/CAM software segment, which accounts for $6.13 billion.
Autodesk, despite not outpacing the software industry's earnings growth of 23.8% with its own 22.7%, shows robust financial health with a significant Return on Equity forecasted at 44.6% in three years. The company's strategic maneuvers, including the recent $1.5 billion unsecured revolving loan facility, underscore its readiness for future investments and operational flexibility. Innovations like integrating safety and change management tools into Autodesk Construction Cloud® highlight its commitment to enhancing construction project efficiency and transparency, positioning it well within the high-growth tech sector despite slower anticipated revenue growth compared to market leaders.
Dive into the specifics of Autodesk here with our thorough health report.
Review our historical performance report to gain insights into Autodesk's's past performance.
Simply Wall St Growth Rating: ★★★★★☆
Overview: CrowdStrike Holdings, Inc. offers cybersecurity solutions both in the United States and internationally, with a market capitalization of approximately $109.64 billion.
Operations: With a market cap of approximately $109.64 billion, CrowdStrike generates revenue primarily through its Security Software & Services segment, which amounts to $3.95 billion.
CrowdStrike Holdings continues to redefine cybersecurity with its AI-driven Falcon platform, particularly highlighted by its recent expansion of threat detection capabilities. In April 2025, the company unveiled significant enhancements to Falcon® Identity Protection and Next-Gen SIEM, addressing the sophisticated landscape of cloud threats and identity theft. These innovations not only strengthen security across hybrid environments but also streamline operations by eliminating the need for multiple security tools. This strategic focus on integrated solutions is crucial as CrowdStrike reported a notable revenue increase to $1.06 billion in Q4 FY2025, up from $845 million in the prior year, despite a shift to a net loss in the same period.
Unlock comprehensive insights into our analysis of CrowdStrike Holdings stock in this health report.
Understand CrowdStrike Holdings' track record by examining our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Datadog, Inc. provides an observability and security platform for cloud applications globally, with a market capitalization of $40.51 billion.
Operations: The company generates revenue primarily from its IT Infrastructure segment, which amounts to $2.83 billion. The platform serves both domestic and international markets, focusing on observability and security for cloud applications.
Datadog's strategic maneuvering in the tech landscape is underscored by its robust earnings growth of 43.8% over the past year, outpacing the software industry's average of 23.8%. Despite a dip in net income from $42.63 million to $24.64 million in Q1 2025, Datadog forecasts revenue growth between $787 million and $791 million for Q2 and anticipates reaching up to $3.235 billion annually. The partnership with Chainguard enhances its container observability solutions, promising more secure software delivery through proactive CVE remediation—a critical edge as it addresses pressing security vulnerabilities within tech infrastructures. This integration not only broadens Datadog's service offerings but also solidifies its position in a competitive market by aligning enhanced security features with substantial revenue trajectories.
Click here and access our complete health analysis report to understand the dynamics of Datadog.
Learn about Datadog's historical performance.
Discover the full array of 234 US High Growth Tech and AI Stocks right here.
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:ADSK NasdaqGS:CRWD and NasdaqGS:DDOG.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Citi Reaffirms Buy on Broadcom (AVGO) Amid Surging AI Revenue
Broadcom Inc. (NASDAQ:AVGO) is one of the 10 best tech stocks to buy according to billionaires right now. On June 9, a Citi analyst raised his price target on Broadcom from $276 to $285 while maintaining a Buy rating. This revision follows Broadcom's second-quarter results, which showed continued strength in AI-related revenue, although overall performance was mixed, as per the analyst, due to some pressure on margins. Broadcom continues to benefit from growing demand in the artificial intelligence space, which remains a key driver of topline performance. The company reported Q2 FY 2025 revenue of $15.0 billion, up 20% year-over-year supported by strong AI semiconductor sales and contributions from VMware. Adjusted EBITDA rose 35% year-over-year to $10.0 billion, implying an EBITDA margin of 67%. A worker assembling the inner circuitry of a semiconductor product. AI-related revenue reached $4.4 billion in Q2, growing 46% year-over-year, driven primarily by demand for AI networking solutions. Management expects this momentum to carry into Q3, with AI semiconductor revenue projected to reach $5.1 billion. This growth is supported by continued investment by hyperscale customers. Looking ahead, Broadcom guided for Q3 FY25 revenue of approximately $15.8 billion and an adjusted EBITDA margin of at least 66% of revenue, which is slightly below versus Q2. However, the company's margin outlook raised some concerns. According to the analyst, an increased contribution of semiconductor sales in total sales has put pressure on profitability. In response, management has adjusted its guidance, which indicates a slightly lower margin in the near term. Broadcom Inc. (NASDAQ:AVGO) is a global technology company that designs, develops, and supplies a wide range of semiconductor and infrastructure software solutions. The company's products play a crucial role in enterprise and data center networking, broadband access, storage systems, smartphones, and wireless communications. Broadcom's extensive portfolio includes solutions for data center networking, storage, and security, making it a key player in the data center ecosystem. While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 hours ago
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.